Taking
nature’s lead in antimicrobials

 

Novarifyn® (NP432) is antibacterial peptide with a number of key benefits over conventional antibiotic therapies and the clear potential to succeed where existing treatments for a number of bacterial infections, including those caused by MRSA, P. aeruginosa, and C. difficile, are failing.

Importantly, Novarifyn has no or at least very low risk of acquired resistance development in target pathogens compared to conventional antibiotics. This is due to a rapid, membrane-lysing bactericidal mechanism of action.

Clinical and Commercial Development

Novarifyn is a preclinical asset (set to enter clincial development 2017).

Novarifyn is potently and rapidly bactericidal in vitro against clinically and economically important bacterial pathogens – including multi drug resistant Gram negative and Gram positive species

Novarifyn is well-tolerated and demonstrated efficacy in in vivo infection models.

NovaBiotics has developed NP432 from the same technology platform as Novexatin and Novamycin and so combined the route to clinic anticipated for this novel peptide antibacterial has already been significantly de-risked.

Molecule Class and Formulation
Novarifyn can be formulated to facilitate topical, parenteral, and aerosol delivery and is not sensitive to physiologic salt or pH conditions.

Mechanism of Action

Novarifyn has a mmechanism of action based on membrane perturbation and lysis which rapidly kills bacteria (not merely inhibiting growth)

NP423 is active against a range of difficult to treat pathogens including MRSAP. aeruginosa, C. difficile, A. baumannii  and E. Coli.  

 

Global Market

Bacterial infectious diseases represent a massive unmet medical need globally. The worldwide market for antibacterials is considerable at $45 billion; more than 50% of the overall anti-infectives market at $65 billion. Despite this significant global opportunity, the sector remains dominated by a relatively small number of drug classes, some having existed in clinical practice for over 50 years. R&D efforts are also focused on re-invigorating these existing/older drug classes versus the creation of new classes, typically via new formulations to secure IP, rather than launch of new compounds.

NovaBiotics is pioneering anti-infective peptide drug discovery and development for bacterial disease and is targeting difficult-to-treat, potentially life-threatening infections with its Novarifyn technology  Uniquely, Novarifyn effectively kills antibiotic sensitive and resistant bacteria both in planktonic (“free”) form and in more challenging biofilm infections (biofilms serve as a means of protection for bacteria against the immune system and antibiotic therapies and a main reason why many infections remain insensitive to conventional antibiotics).